Cargando…
B7-H3/CD276: An Emerging Cancer Immunotherapy
Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member o...
Autores principales: | Zhou, Wu-Tong, Jin, Wei-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326801/ https://www.ncbi.nlm.nih.gov/pubmed/34349762 http://dx.doi.org/10.3389/fimmu.2021.701006 |
Ejemplares similares
-
Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer
por: Inamura, Kentaro, et al.
Publicado: (2018) -
Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma
por: Liang, Jiayu, et al.
Publicado: (2020) -
Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets
por: Marques, Rui Ferreira, et al.
Publicado: (2023) -
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
por: Getu, Ayechew Adera, et al.
Publicado: (2023) -
Emergence of the CD226 Axis in Cancer Immunotherapy
por: Conner, Michael, et al.
Publicado: (2022)